362 related articles for article (PubMed ID: 31928256)
1. Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems.
Singh VK; Seed TM
Expert Opin Pharmacother; 2020 Feb; 21(3):317-337. PubMed ID: 31928256
[No Abstract] [Full Text] [Related]
2. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use.
Singh VK; Hanlon BK; Santiago PT; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):885-906. PubMed ID: 28657400
[TBL] [Abstract][Full Text] [Related]
3. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
Singh VK; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
[TBL] [Abstract][Full Text] [Related]
4. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
Singh VK; Garcia M; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
[TBL] [Abstract][Full Text] [Related]
5. Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.
Singh VK; Romaine PL; Seed TM
Health Phys; 2015 Jun; 108(6):607-30. PubMed ID: 25905522
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of amifostine for the acute radiation syndrome.
Singh VK; Seed TM
Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
[No Abstract] [Full Text] [Related]
7. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure.
Singh VK; Seed TM
Expert Opin Investig Drugs; 2020 May; 29(5):429-441. PubMed ID: 32450051
[TBL] [Abstract][Full Text] [Related]
8. Potential utility of peptides against damage induced by ionizing radiation.
Shaghaghi Z; Alvandi M; Nosrati S; Hadei SK
Future Oncol; 2021 Apr; 17(10):1219-1235. PubMed ID: 33593084
[TBL] [Abstract][Full Text] [Related]
9. Molecular hydrogen: A potential radioprotective agent.
Hu Q; Zhou Y; Wu S; Wu W; Deng Y; Shao A
Biomed Pharmacother; 2020 Oct; 130():110589. PubMed ID: 32763820
[TBL] [Abstract][Full Text] [Related]
10. Radioprotective countermeasures for radiation injury (Review).
Liu L; Liang Z; Ma S; Li L; Liu X
Mol Med Rep; 2023 Mar; 27(3):. PubMed ID: 36799170
[TBL] [Abstract][Full Text] [Related]
11. Twenty five years of the National Academy of Medical Sciences of Ukraine - progress and priorities for future of radiation medicine and biology.
Bazyka D
Probl Radiac Med Radiobiol; 2017 Dec; 22():10-14. PubMed ID: 29286493
[TBL] [Abstract][Full Text] [Related]
12. Development of radiation countermeasure agents for acute radiation syndromes.
Guan B; Li D; Meng A
Animal Model Exp Med; 2023 Aug; 6(4):329-336. PubMed ID: 37642199
[TBL] [Abstract][Full Text] [Related]
13. Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.
Singh VK; Seed TM
Front Pharmacol; 2021; 12():624844. PubMed ID: 34040517
[TBL] [Abstract][Full Text] [Related]
14. Radiation Protection and Mitigation by Natural Antioxidants and Flavonoids: Implications to Radiotherapy and Radiation Disasters.
Yahyapour R; Shabeeb D; Cheki M; Musa AE; Farhood B; Rezaeyan A; Amini P; Fallah H; Najafi M
Curr Mol Pharmacol; 2018; 11(4):285-304. PubMed ID: 29921213
[TBL] [Abstract][Full Text] [Related]
15. Radiation countermeasure agents: an update.
Dumont F; Le Roux A; Bischoff P
Expert Opin Ther Pat; 2010 Jan; 20(1):73-101. PubMed ID: 20021286
[TBL] [Abstract][Full Text] [Related]
16. [Peculiarities of antioxidants as radioprotectors under radiation damage of different extent].
Shishkina LN
Radiats Biol Radioecol; 2013; 53(5):536-44. PubMed ID: 25434176
[TBL] [Abstract][Full Text] [Related]
17. Radiation countermeasure agents: an update (2011-2014).
Singh VK; Newman VL; Romaine PL; Wise SY; Seed TM
Expert Opin Ther Pat; 2014 Nov; 24(11):1229-55. PubMed ID: 25315070
[TBL] [Abstract][Full Text] [Related]
18. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation countermeasures.
Mishra KN; Moftah BA; Alsbeih GA
Biomed Pharmacother; 2018 Oct; 106():610-617. PubMed ID: 29990850
[TBL] [Abstract][Full Text] [Related]
19. Modifiers of radiation effects in the eye.
Kleiman NJ; Stewart FA; Hall EJ
Life Sci Space Res (Amst); 2017 Nov; 15():43-54. PubMed ID: 29198313
[TBL] [Abstract][Full Text] [Related]
20. Radiation protectants: current status and future prospects.
Seed TM
Health Phys; 2005 Nov; 89(5):531-45. PubMed ID: 16217197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
